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abstract:Natural killer (NK) cells are a typeof lymphocyte circulating in peripheral blood namedbecauseof their effector functions in killing
target cells. Immune cells that share similar phenotypic characteristics but are poor killers populate the uterine lining at implantation and during
early pregnancywhen theplacenta is established.The functionsof theseuterineNK(uNK) cells areessentially unknownbut available data point to
a role in regulating placentation in concertwith other elements of the decidua and invading trophoblast cells.Despite the lackof scientiﬁc rationale
and advice fromclinical governing bodies, such as theHuman Fertilisation andEmbryologyAuthority, an increasing rangeof tests and therapies are
still offered to women undergoing IVF or attending recurrent miscarriage clinics based on the myth that uterine NK cells need suppressing to
prevent damage to the embryo. New treatments can be introduced at whim with subsequent demands for expensive trials to prove/disprove
their efﬁcacy. The evidence that targeting uNKor peripheral bloodNK cells assists womenwith recurrent pregnancy failure is lacking. Healthcare
professionals and patients should very carefully evaluate thepracticeof immunomodulation to enhancepregnancyoutcome.Adiscussion on how
tomove towards stricter regulationof immunotherapy innon-hospital settings is nowneededbecause it is clear that thepotential risks andcostsof
these therapies outweigh any beneﬁts.
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Introduction
Nearly 25 years ago three British scientists described a new type of
immune cell in the human uterine mucosa (Bulmer et al., 1991; King
and Loke, 1991; Starkey et al., 1991). Although these cells had previously
been noted and given a variety of names (e.g. endometrial granulocytes,
K cells), it was only around 1990 that they were identiﬁed as a type of
lymphocyte belonging to the natural killer (NK) lineage. The cells were
initially called uterine large granular lymphocytes based on their size
and prominent cytoplasmic granules (King and Loke, 1991). When
similar cells in the decidua of some rodents and primates were also
found to be NK-lineage cells, the term ‘uterine NK cells’ (uNK) was
introduced to describe these cells present during haemochorial placen-
tation in a range of species (Croy et al., 1996; King et al., 1996).
NK cells circulating in blood were so called because they have the
innate ability to kill some leukemic cell lines in vitro (Herberman et al.,
1975; Kiessling et al., 1975). Retrospectively, uNK is a misnomer as
they are poor at killing these same cell lines (King et al., 1989). Regret-
tably, this name has been a driver for the myths that uNK can kill the
embryo and are responsible for reproductive failure in women with re-
current miscarriage and failed IVF. The actual contribution of these ma-
ternal immune cells to success or failure in women with infertility and
recurrent miscarriage is still unknown but there is no evidence that
they kill trophoblast cells in these conditions (Moffett and Colucci,
2014). Despite this a large industry has grown up to treat women
deemed to have excessively potent uterine ‘killers’. Apart from the
lack of evidence base for these treatments, they are not without risk to
young healthy women.
Uterine NK cells
Granulated cells were identiﬁed over 100 years ago in the pregnant
uterine mucosa and even described as a ‘type of leukocyte restricted
to the decidua’ (Weill, 1921). It was not until the advent of immuno-
histochemistry that these cells were conﬁdently identiﬁed as bone
marrow-derived CD45+ leukocytes (Bulmer and Sunderland, 1983).
There is general agreement that the dominant leukocytes present in
themucosa in the luteal phase and in early pregnancy are granulated lym-
phocytes, which are CD56+, but CD32 (so not T cells) and CD192
(not B cells). The CD56+ phenotype assigns them to the NK lineage,
part of a wider group of lymphocytes known as innate lymphoid cells
(ILCs) that all lack antigen speciﬁc receptors generated by somatic
gene rearrangement (T and B cell receptors) and mediate homeostatic
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as well as developmental and defensive functions particularly at mucosal
surfaces (Artis and Spits, 2015).
Peripheral blood NK cells (pbNK) are important as a ﬁrst line of
defence against viruses and are also important in controlling the early
spreadof tumours, functionsmediated by both cytotoxicity and cytokine
secretion. Unlike cytotoxic T cells, this killing can occur without prior
stimulation (Karre, 2008). NK cells therefore play an important role in
early innate immune responses to pathogens such as viruses (Horowitz
et al., 2012). In addition, NK cells drive adaptive immune responses to
infections by inﬂuencing antigen-presenting cells (APC) (Vivier et al.,
2011). In peripheral blood, there are two major types of NK cells; 90%
are CD56dim, CD16+ and 10% are CD56bright, CD162 (Caligiuri,
2008). In contrast, uNK cells are CD56superbright, CD162 and differ rad-
ically frompbNK in other phenotypemarkers and functional assays (King
et al., 1991; Starkey, 1991; Koopman et al., 2003). The classical assay to
assess pbNK function is killingof target cells that lackmajor histocompati-
bility complex class I molecules (known as HLA in humans) because this
rules out any killing from circulating CD8+ cytotoxic T cells that are trig-
gered to kill on recognition of HLA class Imolecules. uNK killing in vitroof
HLA-null target cell lines, such as K562, is very weak compared with
pbNK (King et al., 1989; Ferry et al., 1990). Nevertheless, uNK can de-
granulate and this function can be used as an informative readout
(Xiong et al., 2013).
Where uNKoriginate from is still unclear. Theremight be in utero resi-
dent CD34+ stem cells (Keskin et al., 2007; Vacca et al., 2011) but it is
more likely that uNK arise from immature circulating progenitors that
migrate into the uterine mucosa and develop there (Male et al., 2010).
Whatever their origin, their unique properties are acquired in utero as
CD56+ cells do proliferate and differentiate in the specialized
progesterone-dominatedmicroenvironment of the secretory endomet-
rium and early decidua (Pace et al., 1989).
uNK cells are the dominant immune cells in the uterine mucosa and
account for .30% of cells in the stroma in the late secretory endomet-
rium in humans (Bulmer and Lash, 2005). During pregnancy uNK are
abundant throughout decidua but amass particularly at the site of placen-
tation in close physical proximity to inﬁltrating trophoblast cells (Xiong
et al., 2013). They are also particularly prominent around spiral arteries
and under the basement membrane of endometrial glands. Although
there are some uNK cells still present at term they are really abundant
early in gestation when the placenta is established. This is the time of
rapid placental growth before the accelerated period of fetal growth
that occurs in the second half of gestation (Wolf et al., 1989).
NK cells are present in a range of tissues besides the uterus including
the lymph nodes, thymus, spleen and liver (Yokoyama et al., 2013).
Whilst other tissue NK cells share similarities with uNK cells in that
they are CD56bright, possess poor cytotoxic ability and are functionally
different to pbNK, they differ from uNK cells as they do not possess
the same repertoire of cell-surface receptors and their cellular subsets
are regulated by different transcription factors than observed in uNK
cells (Tayade et al., 2005).
Function of uNK cells
We can conclude from a range of data that there is a population of NK
cells present in the uterinemucosa at implantation and in early pregnancy
that is phenotypically and functionally quite dissimilar from pbNK and all
other known ILC andNK subsets, including tissue resident NK cells. But
thereare stillmanyunknowns, especially the roles of these cells in normal
and abnormal pregnancy. The prevailing view, supported by their tem-
poral and spatial association with the invading extravillous trophoblast
(EVT), is that uNK cells play an important role in building a healthy pla-
centa. A range of angiogenic factors secreted by uNK during decidualisa-
tion may contribute to the modiﬁcation of the structure of pre-existing
arteries, particularly the smooth muscle media (Hanna et al., 2006).
uNK cells may also play a role in decidualization itself since in mice
lacking NK cells the decidua is abnormal and fetal weights are reduced
(Ashkar et al., 2000; Barber and Pollard, 2003).
Both genetic and other circumstantial evidence suggests that uNK con-
tribute to the regulation of placentation by the decidua, the site where a
territorial boundary is drawn between the mother (decidua) and her
baby (trophoblast) (Moffett and Colucci, 2014). It is important to stress
that exactly how they do this is still a mystery. When the spiral arteries
are invadedbyEVTcompletedestructionof themedia is seen, anessential
modiﬁcation to increasebloodﬂowto the fetus.Manystudies suggest uNK
can alter the depth and patternof trophoblast invasion, best shown in a rat
model (Chakraborty et al., 2011). From the limited good quality evidence
available, by acting either directly on the arteries and/or on invading
trophoblast, uNKmaintain the balance between excessive trophoblast in-
trusion and defective placentation; the latter increases the risk of miscar-
riage and pre-eclampsia and other disorders known collectively as the
Great Obstetric Syndromes (Brosens et al., 2011).
Evidence for the need to activate uNK comes from genetic studies
in pre-eclampsia where variants of NK receptor genes, killer
immunoglobulin-like receptors (KIR), have been analysed in case–
control cohorts. KIR are highly polymorphic, expressed by uNK and
bind and respond to fetal HLA-C molecules present on EVT (Sharkey
et al., 2008). TheHLA-C locus is also polymorphic and this extreme vari-
ability inbothmaternalKIR and fetalHLA-C ligandsmeans thateachpreg-
nancy is likely to have different combinations, even from the same
parents (Moffett et al., 2015). Women with a set of KIR genes that
confer highly inhibitory signals to uNK are at risk of pre-eclampsia
when the fetus inherits a paternal HLA-C allele that carries a C2
epitope. Women are protected if they happen to possess KIR2DS1, an
activating KIR, which also binds this C2 epitope (Hiby et al., 2004,
2010). Our own studies supported by in vitro experiments thus indicate
that a certain degree of uNK cell activation promotes trophoblast inva-
sion (Xiong et al., 2013). Mouse studies also show that strong inhibition
of uNK impedes both uterine vascular remodelling and fetal growth
(Kieckbusch et al., 2014). This is all in keeping with the complete lack
of experimental evidence for the view that uNK need ‘suppressing’.
NK testing
Despite this, soon after uNKweredescribed, the notion that killing of the
embryo by uNK was responsible for miscarriages and IVF failure was
mooted. A clinic in Chicago, IL, USA, introduced blood tests to
measure numbers of pbNK and their levels of killing in women with re-
productive failure (Chao et al., 1995). Any woman deemed to have
‘high’ levels was then offered a range of therapies (Ruiz et al., 1996).
These treatments have changed over the years but are intended to sup-
press NK cells from attacking the embryo or to have other ill-deﬁned
effects on the maternal immune system.
Quotes from a number of websites are revealing: ‘If the women’s
immune system for any reason identiﬁes the embryo as foreign, only
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one thing will happen—she will begin to ﬁght it’ (Ndukwe, 2015); ‘we
found that some women’s natural killer cells are so aggressive they
attack the pregnancy, thinking the foetus is a foreign body’ (Shehata,
2014); ‘while these cells differ from those found in the blood, it is fortuit-
ous thatwe canmeasure the natural killer activity of the cells in the blood
and learn much about the activity of those within the uterus’; ‘there are
couples who produce embryos that are misinterpreted by the immune
system as foreign objects or even cancer cells. These embryos are repu-
diated andeach attempt at pregnancymakes theproblemworse until the
uterus behaves like a “den of lions” and every pregnancy attempt fails’
(Alan E. Beer Centre&, 2015).
These emotive claims lack any supporting evidence. uNK cells are
never in contact with the embryo; they are only in contact with placental
trophoblast cells. They cannot kill trophoblast unless exposed to high
doses of interleukin (IL)-2, a cytokine absent from the normal pregnant
uterus (Jokhi et al., 1994; Lim et al., 1998). Furthermore, uNK cells are
quite distinct from pbNK cells and any parameter measured from a
blood test cannot reﬂect their functional capabilities. This is unsurprising
since the expression of activating and inhibitory receptors that regulate
NK cell function differs considerably between pbNK and uNK
(Moffett-King, 2002; Sharkey et al., 2008).
The normal range forNK cell numbers and activity in peripheral blood
from normal individuals varies widely, at 5–30% of mononuclear cells
(Bisset et al., 2004; Sacks et al., 2012). Notably, however, pbNK are
never measured routinely in any clinical condition apart from haemato-
logical disorders, such as leukaemia, because no clinically useful informa-
tion is obtained. Indeed, because of the absence of any routine tests for
pbNK inmosthospital laboratories, blood samples taken in fertility clinics
in the UK are often sent abroad for a range of expensive ‘immune’ tests
including equally questionable ‘Th1/Th2 ratios’. Although there is no ra-
tionale for measuring any parameters in pbNK, this ‘NK testing’ has now
spread across theworld and is commonplace in a number of well-known
fertility clinics.
In 2008 advice from the Royal College ofObstetricians andGynaecol-
ogists (Rai, 2008) echoedby theHumanFertilisationandEmbryologyAs-
sociation (HFEA) stated that ‘measurement of peripheral blood NK cell
numbers or activity as a surrogatemarker of events at thematernal-fetal
interface is inappropriate’ and is ‘no better than tossing a coin’ (Rai et al.,
2005; HFEA, 2010). Despite this and the current paucity of strong evi-
dence to suggest otherwise, it is interesting to speculatewhy this practice
continues unabated today. One obvious reason is the pervasive and ac-
cessible idea that suppression of the immune system has a role in preg-
nancy success, although this is basedonold ideasnot relevant toNKcells.
T cell suppression is certainly needed for successful transplantation
and it was Peter Medawar himself who introduced the concepts of the
fetal transplant and maternal immunosuppression (Medawar, 1953).
The possible need for T cell tolerance to accommodate the fetus has
been extensively researched for decades (Mellor and Munn, 2000).
Despite this, 60 years on there is still no experimental evidence to
support the notion that systemicmaternal tolerance of T cells is required
for successful human pregnancy (Colucci et al., 2014), although elegant
mouse experiments have provided evidence that lack of regulatory T
cells does lead to fetal demise (Rowe et al., 2012; Samstein et al.,
2012). One reason for the apparent inconsistency with the mouse
studies is the difﬁculty in distinguishing between systemicTcell responses
to fetal somatic cells crossing into the maternal circulation from those
local uterine T cell responses to invading EVT (Moffett and Colucci,
2014; Nancy and Erlebacher, 2014). T cells are normally relatively
sparse at the site of placentation and have not been shown to damage
the implanting placenta in humans. In addition, B cells or plasma cells
are absent in decidua, which suggests that antibodies to invasive EVT
are normally never generated. Thus, there is no convincing evidence
that IVF failure or recurrent pregnancy loss result from adverse adaptive
T or B cell immune responses to the placenta.
Measurement of uNK cells
More recently attempts have been made to correlate numbers of uNK
cells during the luteal phase with successful implantation/placentation
(Tuckerman et al., 2007; Kuroda et al., 2013). Amajor problem in count-
ing uNK in endometrium is their huge variability over themenstrual cycle,
with a rapid surge in numbers after ovulation due to proliferation trig-
gered by progesterone-mediated induction of IL-15 in stromal cells
(Wilkens et al., 2013). In addition, the presence of oedema, depth
from the surface epithelium and site in the uterus can all affect uNK
numbers. Even without these problems there is no reason to correlate
numbers of uNK present prior to pregnancy with any putative harmful
or beneﬁcial function. As has been pointed out by others, because
uNK numbers do change so dramatically over the luteal phase, any alter-
ation from normal control women (women of reproductive age with no
known infertility) may just reﬂect maturational delay or acceleration
affecting the whole mucosa (Russell et al., 2013). In other words, any
deviations in the hypothalamic/pituitary/ovarian (HPO) axis will affect
all components of the cycling mucosa including uNK proliferation
(Kosova et al., 2015). Pre-conceptual elevated numbers of uNK can be
reduced by prednisolone in women with recurrent miscarriage
(Quenby et al., 2005) but this correlation does not account for the
wider effects of steroid therapy on the HPO axis and the global effect
of steroids on lymphocytes. Given the invasive procedure necessary
and the difﬁculty in standardizing this test between different labs and
operators, counting uNK in endometrium should only be considered
in research settings. All these tests are expensive; even in clinics where
customers are warned that ‘there is no absolute evidence that uterine
NK cells are destructive and attack placental or embryonic cells’
(Natural Killer Cell Testing, 2015) couples can expect to pay .£1000
for a combined uNK and pbNK test prior to undergoing an assisted re-
production cycle.
Range of ‘immune’ treatments
In the1980swomenweregiven infusionsof paternal leukocytes for treat-
ment of infertility and recurrent miscarriage, now known as lymphocyte
immunotherapy (LIT). The rationale and mechanism for this was always
confused but was supposed to stimulate a ‘beneﬁcial’ immune response
to paternal antigens (Mowbray et al., 1985). This treatment was subse-
quently banned in 2002 by the US Food and Drug Administration
(FDA), who wrote to all physicians believed to be using LIT as a
therapy ‘that the injectable products used do not have the required
FDA approval and are considered investigational drugs that pose
several safety concerns’ (Wong et al., 2014). The reasoning behind LIT
was always unclear because the systemicmaternal immune system is nor-
mally stimulatedbypaternal antigensexpressedby the fetus, as illustrated
by the generation of maternal antibodies speciﬁc to paternal HLA allo-
types and blood group antigens (e.g. Rhesus D). Importantly, this
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needs to be considered quite separately from uterine immune responses
to EVT that occur during placentation.
Over the subsequent years a wide range of other therapies has been
introduced seemingly at random: these include tumour necrosis factor
alpha (TNFa) inhibitors, intravenous immunoglobulins (IVIg), Intralipid,
prednisolone or dexamethasone and granulocyte-colony stimulating
factor. Table I summarizes the indications for the normal use of these
therapies, their side effects and costs. Some of these therapies will cer-
tainly affect the maternal immune system but not necessarily in a beneﬁ-
cial way. The risk of infection, especially tuberculosis, is a side effect of
TNFa inhibitors, steroids are globally immunosuppressive and IVIg
(not recommended for use in IVF failure or recurrent pregnancy loss
by the UK Dept. of Health) can blockade Fc receptors on other
immune cells, alter cytokine production and neutralize complement
components, thereby possibly interfering with maternal immune
defence mechanisms to pathogens. A salutary report describes a case
of systemic candidiasis presenting at 18 weeks gestation resulting in
fetal loss following administration of TNFa inhibitor, prednisolone and
Intralipid during assisted reproduction (Akhanoba, 2014). Around 40%
of IVIg users will experience mild adverse events, and in serious cases
can suffer from anaphylaxis (Berger, 2013). An additional ethical
concern is the diversion of IVIg from patients with serious conditions ne-
cessitating strict allocation of the limited supplies available (Department
of Health, 2011). Whether or how any of these therapies might affect
uNK function is unknown and hard to predict, givenwe are still so uncer-
tain of the exact role of uNK in successful or failing pregnancy.
Conclusions
A recent Cochrane review found ‘Paternal cell immunization, third-
party donor leukocytes, trophoblast membranes, and intravenous
immunoglobulin provide no signiﬁcant beneﬁcial effect over placebo in
improving the live birth rate’ (Wong et al., 2014). Introducingmore ther-
apieswith nounderpinning frombasic science and then testing thesewith
costly trials cannot be the way forward. The difﬁculties in studying
trophoblast/decidua interactions events in normal and abnormal preg-
nancies in the ﬁrst few weeks of pregnancy are considerable but this
must be the focus of research by clinicians and at the bench.
Since writing a similar review 10 years ago, it is worth reﬂecting why
there has been limited scientiﬁc progress yet even more therapies that
offer no beneﬁt and possible harm. Private IVF and miscarriage clinics
can use these treatments at whim driven by commercial gain because,
whilst HFEA approved licences are required to perform IVF, no such
licences are required for reproductive immunology treatments. It is
understandable that commercial success and patient demand for the
continued development of such tests and treatments continues to
drive clinical practice. Even the most informed patients are often
willing to ‘try anything’ to achieve a live birth. The misrepresentation
by the media of poorly designed clinical research related to uNK func-
tion—e.g. ‘My body tried kill my baby’ (Fricker, 2007) and ‘The killer
cells that robbed me of four babies’ (Barber, 2011)—has only served
to heighten this demand (Shreeve and Sadek, 2012). This can leave clin-
icians in potentially compromising situationswhere a lackof scientiﬁc evi-
dence can be superseded by a patient’s will to fall pregnant through the
use of ‘safe’ immunomodulation.
We acknowledge that some clinicians do appear to ‘believe fervently’
in the merits of immunotherapy (Fishel, 2013). Nonetheless, it is surely
no longeracceptable for licensedmedical practitioners to continue to ad-
minister and proﬁt from potentially unsafe and unproven treatments,
based on belief and not scientiﬁc rationale. Allowing the regular admin-
istration of potentially harmful medicines to go virtually unchecked sets
a dangerous precedent, irrespective of the assumed clinical beneﬁt. In
.............................................................................................................................................................................................
Table I A summary of agents used for immunomodulation in assisted reproductive technology.
Drug Cost Common clinical uses Some known side effects or adverse
events
Lipid Emulsion
e.g. Intralipid&
Approx. £300 per infusion in
clinic setting
Parenteral nutrition, administered with
propofol, cardio-protection in bupivacaine
toxicity (Picard, 2006)
Hepatomegaly, jaundice, cholestasis,
splenomegaly, thrombocytopenia, leukopenia and
fatoverload syndrome (,1%occurrence in clinical
trials) (FDA, 2007)
Intravenous
Immunoglobulin (IVIG)
Approx. £1500 per infusion
(may vary depending on
dose) in clinic setting
Primary and secondary antibody deﬁciency
states, haematological disorders, neurological
conditions, other uses, e.g. solid organ
transplantation (DoH, 2011)
Aseptic meningitis, renal failure, thromboembolism,
haemolytic reactions, anaphylactic reactions, lung
disease, enteritis, dermatologic disorders and
infectious diseases (Stiehm, 2013)
Corticosteroids Net price 28-tablet pack
£1.86 (BNF, 2015)
Suppression of inﬂammatory/allergic disorders,
inﬂammatory bowel disease, asthma, croup,
rheumatic disease, eye and ear conditions
(BNF, 2015)
Gastric ulceration, Cushing’s syndrome, diabetes,
hypocalcaemia, osteoporosis, skin thinning, dry
skin, high blood sugar (BNF, 2015)
Anti-tumour necrosis
factor (Anti-TNF)
Net price £352.14/40 mg
syringe (BNF, 2015)
Autoimmune disorders, e.g. rheumatoid
arthritis, ankylosing spondylitis, inﬂammatory
bowel disease, psoriasis (BNF, 2015)
Infection, lymphoma, demyelinating disease,
autoantibody induction, congestive heart failure,
injection site reactions, lupus-like syndrome
(Scheinfeld, 2004)
Granulocyte-Colony
Stimulating Factor (G-CSF)
Net price 600 mcg/ml
£52.70, 0.5-ml preﬁlled
syringe (BNF, 2015)
Neutropenia (various clinical types), severe or
recurrent infections in advanced human
immunodeﬁciency virus infection (BNF, 2015)
Mucositis, splenic enlargement, hepatomegaly,
transient hypotension, epistaxis, urinary
abnormalities, osteoporosis, exacerbation of
rheumatoid arthritis, anaemia, pseudogout
(BNF, 2015)
BNF, British National Formulary; DoH, Department of Health; FDA, Food and Drug Administration.
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accordance with the major clinical governing bodies, healthcare profes-
sionals and patients should very carefully evaluate the practice of immu-
nomodulation to enhance pregnancy outcome. The time has also come
for amove towards stricter regulation of immunotherapy in non-hospital
settings.
Acknowledgements
We thank Francesco Colucci, Gordon Smith, Melanie Davies and Hilary
Critchley for their useful comments.
Authors’ roles
N.S. wrote the manuscript. A.M. provided the conceptual ideas, wrote
the manuscript and approved of the ﬁnal submitted version.
Funding
A.M. acknowledges funding support from the Wellcome Trust and
Centre for Trophoblast Research, University of Cambridge, UK.
Funding to pay the Open Access publication charges for this article
was provided by the University of Cambridge.
Conﬂict of interest
None declared.
References
Akhanoba F,MacDougall J, Mathur R, HassanW. Severe systemic candidiasis
following immunomodulation therapy in in vitro fertilisation-embryo
transfer (IVF-ET). BMJ Case Rep 2014;2014:1–4.
Alan E. Beer Centre. Centre for reproductive immunology and genetics.
http://www.repro-med.net (accessed on 29 January 2015).
Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015;
517:293–301.
Ashkar AA, Di Santo JP, Croy BA. Interferon gamma contributes to initiation
of uterine vascular modiﬁcation, decidual integrity, and uterine natural
killer cell maturation during normal murine pregnancy. J Exp Med 2000;
192:259–270.
Barber R. The killer cells that robbedmeof four babies: TV star SallyMeenon
her struggle to have two healthy daughters. Daily Mail January 2011.
http://www.dailymail.co.uk/health/article-1343115/TV-star-Sally-Meen-
The-killer-cells-robbed-babies.html (accessed on 07/02/2015).
Barber EM, Pollard JW. The uterine NK cell population requires IL-15 but
these cells are not required for pregnancy nor the resolution of a Listeria
monocytogenes infection. J Immunol 2003;171:37–46.
Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013;
1:558–566.
Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for
peripheral blood lymphocyte phenotypes applicable to the healthy adult
population in Switzerland. Eur J Haematol 2004;72:203–212.
British National Formulary (BNF). Accessing BNF online. https://www.bnf.
org/bnf/login.htm (accessed on 12/02/2015).
Brosens I, Pijnenborg R, Vercruysse L, Romero R. The ‘Great Obstetrical
Syndromes’ are associated with disorders of deep placentation. Am J
Obstet Gynecol 2011;204:193–201.
Bulmer JN, Lash GE. Human uterine natural killer cells: a reappraisal. Mol
Immunol 2005;42:511–521.
Bulmer JN, SunderlandCA.Bone-marroworigin of endometrial granulocytes
in the early human placental bed. J Reprod Immunol 1983;5:383–387.
Bulmer JN,MorrisonL, LongfellowM,RitsonA,PaceD.Granulated lymphocytes
in human endometrium: histochemical and immunohistochemical studies.
Hum Reprod 1991;6:791–798.
Caligiuri MA. Human natural killer cells. Blood 2008;112:461–469.
Chakraborty D, Rumi MA, Konno T, Soares MJ. Natural killer cells direct
hemochorial placentation by regulating hypoxia-inducible factor
dependent trophoblast lineage decisions. Proc Natl Acad Sci USA 2011;
108:16295–16300.
Chao KH, Yang YS, HoHN, Chen SU, ChenHF, Dai HJ, Huang SC, Gill TJ III.
Decidual natural killer cytotoxicity decreased in normal pregnancy but not
in anembryonic pregnancy and recurrent spontaneous abortion. Am J
Reprod Immunol 1995;34:274–280.
Colucci F, Moffett A, Trowsdale J. Medawar and the immunological paradox
of pregnancy: 60 years on. Eur J Immunol 2014;44:1883–1885.
Croy BA, Luross JA,GuimondMJ, Hunt JS. Uterine natural killer cells: insights
into lineage relationships and functions from studies of pregnancies in
mutant and transgenic mice. Nat Immun 1996;15:22–33.
Department of Health (DoH). Clinical guidelines for immunoglobulin use.
2011. http://www.ivig.nhs.uk/documents/dh_129666.pdf (accessed on
29 January 2015).
Ferry BL, Starkey PM, Sargent IL, Watt GM, Jackson M, Redman CW. Cell
populations in the human early pregnancy decidua: natural killer activity
and response to interleukin-2 of CD56-positive large granular lymphocytes.
Immunology 1990;70:446–452.
Fishel S. Evidence-basedmedicine and the role of theNationalHealth Service
in assisted reproduction. Reprod Biomed Online 2013;27:568–569.
Food andDrug Administration (FDA). Intralipid 20%. A 20% IV fat emulsion.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017643s
072,018449s039lbl.pdf (accessed on 29 January 2015).
Fricker J. My body tried to kill my baby. Daily Mail, July 2007. http://www.
dailymail.co.uk/health/article-464381/My-body-tried-kill-baby.html
(accessed on 07/02/2015).
Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenﬁeld C, Natanson-
Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I et al.Decidual NK
cells regulate key developmental processes at the human fetal-maternal
interface. Nat Med 2006;12:1065–1074.
Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse
lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of
reactivity and speciﬁcity. Int J Cancer 1975;16:216–229.
Hiby SE, Walker JJ, O’shaughnessy KM, Redman CW, Carrington M,
Trowsdale J, Moffett A. Combinations of maternal KIR and fetal HLA-C
genes inﬂuence the risk of preeclampsia and reproductive success. J Exp
Med 2004;200:957–965.
Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH,
Walker JJ, Redman CW, Morgan L et al. Maternal activating KIRs protect
against human reproductive failure mediated by fetal HLA-C2. J Clin
Invest 2010;120:4102–4110.
Horowitz A, Stegmann KA, Riley EM. Activation of natural killer cells during
microbial infections. Front Immunol 2012;2:88.
Human Embryology and Fertilisation Agency (HFEA). Reproductive Immun-
ology. http://www.hfea.gov.uk/fertility-treatment-options-reproductive-
immunology.html (accessed on 29 January 2015).
Jokhi PP, King A, Sharkey AM, Smith SK, Loke YW. Screening for cytokine
messenger ribonucleic acids in puriﬁed human decidual lymphocyte
populations by the reverse-transcriptase polymerase chain reaction.
J Immunol 1994;153:4427–4435.
Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008;
9:477–480.
Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD,
Koopman LA, Strominger JL. TGFbeta promotes conversion of CD16+
Uterine natural killer cells in assisted reproduction 5
 at U
niversity of Cam
bridge on June 3, 2015
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
peripheral bloodNK cells intoCD16-NK cells with similarities to decidual
NK cells. Proc Natl Acad Sci USA 2007;104:3378–3383.
Kieckbusch J,Gaynor LM,MoffettA,Colucci F.MHC-dependent inhibitionof
uterine NK cells impedes fetal growth and decidual vascular remodelling.
Nat Commun 2014;5:3359.
Kiessling R, Klein E,Wigzell H. ‘Natural’ killer cells in themouse. I. Cytotoxic
cells with speciﬁcity for mouse Moloney leukemia cells. Speciﬁcity and
distribution according to genotype. Eur J Immunol 1975;5:112–117.
King A, Loke YW. On the nature and function of human uterine granular
lymphocytes. Immunol Today 1991;12:432–435.
King A, Birkby C, Loke YW. Early human decidual cells exhibit NK activity
against the K562 cell line but not against ﬁrst trimester trophoblast. Cell
Immunol 1989;118:337–344.
King A, Balendran N, Wooding P, Carter NP, Loke YW. CD3- leukocytes
present in the human uterus during early placentation: phenotypic and
morphologic characterization of the CD56++ population. Dev Immunol
1991;1:169–190.
King A, Burrows T, Loke YW. Human uterine natural killer cells. Nat Immun
1996–1997;15:41–52.
Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F,
Masch R, Lockwood CJ, Schachter AD, Park PJ et al.Human decidual
natural killer cells are a unique NK cell subset with immunomodulatory
potential. J Exp Med 2003;198:1201–1212.
Kosova G, Stephenson MD, Lynch VJ, Ober C. Evolutionary forward
genomics reveals novel insights into the genes and pathways
dysregulated in recurrent early pregnancy loss. Hum Reprod 2015;
3:519–529.
Kuroda K, Venkatakrishnan R, James S, Sˇucurovic S, Mulac-Jericevic B,
Lucas ES, Takeda S, Shmygol A, Brosens JJ, Quenby S. Elevated
periimplantation uterine natural killer cell density in human
endometrium is associated with impaired corticosteroid signaling in
decidualizing stromal cells. J Clin Endocrinol Metab 2013;98:4429–4437.
Lim KJ, Odukoya OA, Ajjan RA, Li TC, Weetman AP, Cooke ID. Proﬁle of
cytokine mRNA expression in peri-implantation human endometrium.
Mol Hum Reprod 1998;4:77–81.
Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A. Immature
NKcells, capableofproducing IL-22, arepresent in humanuterinemucosa.
J Immunol 2010;185:3913–3918.
Medawar PB. Some immunological and endocrinological problems raised by
the evolution of viviparity in vertebrates: revention of allogeneic fetal
rejection by tryptophan catabolism. Symp Soc Exp Biol 1953;7:320–338.
MellorAL,MunnDH. Immunology at thematernal-fetal interface: lessons for
T cell tolerance and suppression. Annu Rev Immunol 2000;18:367–391.
Moffett A, Colucci F. UterineNK cells: active regulators at thematernal-fetal
interface. J Clin Invest 2014;124:1872–1879.
Moffett A, Hiby SE, Sharkey AM. The role of the maternal immune system in
the regulation of human birthweight. Philos Trans R Soc Lond B Biol Sci 2015;
370. doi:10.1098/rstb.2014.0071.
Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002;
2:656–663.
Mowbray JF, Gibbings C, Liddell H, Reginald PW,Underwood JL, Beard RW.
Controlled trial of treatment of recurrent spontaneous abortion by
immunisation with paternal cells. Lancet 1985;1:941–943.
Nancy P, ErlebacherA. T cell behavior at thematernal-fetal interface. Int J Dev
Biol 2014;58:189–198.
Natural Killer Cell Testing. What do natural killer cells do? http://www.
naturalkillercells.co.uk/natural-killer-cell-research-and-development-ideas/
10-what-are-natural-killer-cells (accessed on 04/02/2015).
Ndukwe G. Reproductive Immunology. Direct quotation. http://www.zita
west.com/assisted-fertility/treatment-options/reproductive-immunology/
(accessed on 29 January 2015).
Pace D, Morrison L, Bulmer JN. Proliferative activity in endometrial stromal
granulocytes throughout menstrual cycle and early pregnancy. J Clin Pathol
1989;42:35–39.
Picard J,MeekT. Lipid emulsion to treat overdose of local anaesthetic: the gift
of the glob. Anaesthesia 2006;61:107–109.
Quenby S, Kalumbi C, Bates M, Farquharson R, Vince G. Prednisolone
reduces preconceptual endometrial natural killer cells in women with
recurrent miscarriage. Fertil Steril 2005;84:980–984.
Rai R. Immunological testing and interventions for reproductive failure.
Scientiﬁc impact paper no. 5. 2008. https://www.rcog.org.uk/globalassets/
documents/guidelines/scientiﬁc-impact-papers/sip_5.pdf (accessed on
04/02/2015).
Rai R, SacksG, TrewG.Natural killer cells and reproductive failure—theory,
practice and prejudice. Hum Reprod 2005;20:1123–1126.
Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory
memory that sustains anergy to fetal antigen. Nature 2012;490:
102–106.
Ruiz JE, Kwak JY, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, Beer AE.
Intravenous immunoglobulin inhibits natural killer cell activity in vivo in
women with recurrent spontaneous abortion. Am J Reprod Immunol
1996;35:370–375.
Russell P, Sacks G, Tremellen K, GeeA. The distribution of immune cells and
macrophages in the endometrium of women with recurrent reproductive
failure. III: Further observations and reference ranges. Pathology 2013;
45:393–401.
Sacks G, Yang Y, Gowen E, Smith S, Fay L, Chapman M. Detailed analysis of
peripheral bloodnatural killer cells inwomenwith repeated IVF failure.Am J
Reprod Immunol 2012;67:434–442.
Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY.
Extrathymic generation of regulatory T cells in placental mammals
mitigates maternal-fetal conﬂict. Cell 2012;150:29–38.
Scheinfeld N. A comprehensive review and evaluation of the side effects of
the tumor necrosis factor alpha blockers etanercept, inﬂiximab and
adalimumab. J Dermatolog Treat 2004;15:280–294.
Sharkey AM, Gardner L, Hiby S, Farrell L, Apps R, Masters L, Goodridge J,
Lathbury L, Stewart CA, Verma S et al. Killer Ig-like receptor expression
in uterine NK cells is biased toward recognition of HLA-C and alters
with gestational age. J Immunol 2008;181:39–46.
Shehata H. Baby born to woman who suffered 20 miscarriages. BBC News.
January 2014. http://www.bbc.co.uk/news/health-25775823 (accessed
on 28 February 2015).
ShreeveN, SadekK. Intralipid therapy for recurrent implantation failure: new
hope or false dawn? J Reprod Immunol 2012;93:38–40.
Starkey PM. Expression on cells of early human pregnancy decidua, of the
p75, IL-2 and p145, IL-4 receptor proteins. Immunology 1991;
73:64–70.
Starkey PM, Clover LM, Rees MC. Variation during the menstrual cycle of
immune cell populations in human endometrium. Eur J Obstet Gynecol
Reprod Biol 1991;39:203–207.
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med
Rev 2013;27:171–178.
Tayade C, Fang Y, Black GP, V A P Jr, Erlebacher A, Croy BA. Differential
transcription of Eomes and T-bet during maturation of mouse uterine
natural killer cells. J Leukoc Biol 2005;78:1347–1355.
Tuckerman E, Laird SM, Prakash A, Li TC. Prognostic value of the
measurement of uterine natural killer cells in the endometrium of
women with recurrent miscarriage. Hum Reprod 2007;22:2208–
2213.
Vacca P, Moretta L, Moretta A, Mingari MC. Origin, phenotype and function
of human natural killer cells in pregnancy. Trends Immunol 2011;
32:517–523. doi: 10.1016/j.it.2011.06.013.
6 Moffett and Shreeve
 at U
niversity of Cam
bridge on June 3, 2015
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL,
Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of
natural killer cells. Science 2011;331:44–49.
Weill P. Etudes sur les leucocytes. I. Les cellules granuleuses des muqueses
intestinale et uterine. Arch. d’Anatomie Microscop 1921;17:77–82.
Wilkens J, Male V, Ghazal P, Forster T, Gibson DA, Williams AR, Brito-
Mutunayagam SL, Craigon M, Lourenco P, Cameron IT et al. Uterine NK
cells regulate endometrial bleeding in women and are suppressed by
the progesterone receptor modulator asoprisnil. J Immunol 2013;191:
2226–2235.
Wolf H, Oosting H, Treffers PE. A longitudinal study of the relationship
between placental and fetal growth as measured by ultrasonography. Am
J Obstet Gynecol 1989;161:1140–1145.
Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage.
Cochrane Database Syst Rev 2014;10:CD000112.
Xiong S, SharkeyAM,Kennedy PR,Gardner L, Farrell LE, ChazaraO, Bauer J,
Hiby SE, Colucci F,Moffett A.Maternal uterineNK cell-activating receptor
KIR2DS1 enhances placentation. J Clin Invest 2013;123:4264–4272.
YokoyamaWM,SojkaDK,PengH,TianZ.Tissue-resident natural killer cells.
Cold Spring Harb Symp Quant Biol 2013;78:149–156.
Uterine natural killer cells in assisted reproduction 7
 at U
niversity of Cam
bridge on June 3, 2015
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
